user
Indian Journal of Cancer
MEDLINESCIScopusWAJCI
统计
Statistics
收录
Papers
主办单位 Wolters Kluwer - Medknow 主管单位 暂无
综合影响因子 0.618834 发行周期 Quarterly
创刊时间 1963 国际刊号 0019-509X
语种 英文 国内刊号 暂无
邮发代号 暂无 出版地 India
2015
2025
搜索
论文
引用数
年份
1
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Caly, Leon
Druce, Julian D.
Catton, Mike G.
Jans, David A.
Wagstaff, Kylie M.
1266
2020
2
The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade
Coutard, B.
Valle, C.
de lamballerie, X.
Canard, B.
Seidah, N. G.
Decroly, E.
1140
2020
3
Present and future arboviral threats
Weaver, Scott C.
Reisen, William K.
951
2010
4
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Yousuke
Gowen, Brian B.
Takahashi, Kazumi
Shiraki, Kimiyasu
Smee, Donald F.
Barnard, Dale L.
745
2013
5
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, Ka-Tim
Wong, Alvina Yin-Lam
Kaewpreedee, Prathanporn
Sia, Sin Fun
Chen, Dongdong
Hui, Kenrie Pui Yan
Chu, Daniel Ka Wing
Chan, Michael Chi Wai
Cheung, Peter Pak-Hang
Huang, Xuhui
Peiris, Malik
Yen, Hui-Ling
636
2020
6
Crimean-Congo hemorrhagic fever
Whitehouse, CA
634
2004
7
Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity
Bente, Dennis A.
Forrester, Naomi L.
Watts, Douglas M.
McAuley, Alexander J.
Whitehouse, Chris A.
Bray, Mike
563
2013
8
The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
Baez-Santos, Yahira M.
St John, Sarah E.
Mesecar, Andrew D.
549
2015
9
Antiviral effect of catechins in green tea on influenza virus
Song, JM
Lee, KH
Seong, BL
515
2005
10
A 3-DIMENSIONAL MODEL TO ANALYZE DRUG-DRUG INTERACTIONS
PRICHARD, MN
SHIPMAN, C
508
1990
11
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
Tang, Tiffany
Bidon, Miya
Jaimes, Javier A.
Whittaker, Gary R.
Daniel, Susan
506
2020
12
Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein
Lei, Jian
Kusov, Yuri
Hilgenfeld, Rolf
489
2018
13
Identification of natural compounds with antiviral activities against SARS-associated coronavirus
Li, SY
Chen, C
Zhang, HQ
Guo, HY
Wang, H
Wang, L
Zhang, X
Hua, SN
Yu, J
Xiao, PG
Li, RS
Tan, XH
468
2005
14
Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds
Lin, CW
Tsai, FJ
Tsai, CH
Lai, CC
Wan, L
Ho, TY
Hsieh, CC
Chao, PDL
433
2005
15
Protease inhibitors targeting coronavirus and filovirus entry
Zhou, Yanchen
Vedantham, Punitha
Lu, Kai
Agudelo, Juliet
Carrion, Ricardo, Jr.
Nunneley, Jerritt W.
Barnard, Dale
Poehlmann, Stefan
McKerrow, James H.
Renslo, Adam R.
Simmons, Graham
423
2015
16
Tick-borne encephalitis
Gritsun, TS
Lashkevich, VA
Gould, EA
390
2003
17
The flavivirus NS1 protein: Molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker
Muller, David A.
Young, Paul R.
386
2013
18
Of chloroquine and COVID-19
Touret, Franck
de lamballerie, Xavier
384
2020
19
Antiviral activities of lactoferrin
van der Strate, BWA
Beljaars, L
Molema, G
Harmsen, MC
Meijer, DKF
379
2001
20
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Rossignol, Jean-Francois
378
2014
21
Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction
Ho, Tin-Yun
Wu, Shih-Lu
Chen, Jaw-Chyun
Li, Chia-Cheng
Hsiang, Chien-Yun
374
2007
22
The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold
Seley-Radtke, Katherine L.
Yates, Mary K.
361
2018
23
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
Furuta, Yousuke
Takahashi, Kazumi
Shiraki, Kimiyasu
Sakamoto, Kenichi
Smee, Donald F.
Barnard, Dale L.
Gowen, Brian B.
Julander, Justin G.
Morrey, John D.
351
2009
24
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
Brown, Ariane J.
Won, John J.
Graham, Rachel L.
Dinnon, Kenneth H., III
Sims, Amy C.
Feng, Joy Y.
Cihlar, Tomas
Denison, Mark R.
Baric, Ralph S.
Sheahan, Timothy P.
347
2019
25
Type 1 interferons as a potential treatment against COVID-19
Sallard, Erwan
Lescure, Francois-Xavier
Yazdanpanah, Yazdan
Mentre, France
Peiffer-Smadja, Nathan
346
2020
26
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Oestereich, Lisa
Luedtke, Anja
Wurr, Stephanie
Rieger, Toni
Munoz-Fontela, Cesar
Guenther, Stephan
341
2014
27
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
De Clercq, E
340
1998
28
Arbidol as a broad-spectrum antiviral: An update
Blaising, Julie
Polyak, Stephen J.
Pecheur, Eve-Isabelle
334
2014
29
INHIBITORY EFFECT OF DEXTRAN SULFATE AND HEPARIN ON THE REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INVITRO
ITO, M
BABA, M
SATO, A
PAUWELS, R
DECLERCQ, E
SHIGETA, S
332
1987
30
Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy
Thiberville, Simon-Djamel
Moyen, Nanikaly
Dupuis-Maguiraga, Laurence
Nougairede, Antoine
Gould, Ernest A.
Roques, Pierre
de Lamballerie, Xavier
330
2013
31
Antiviral drugs for cytomegalovirus diseases
Biron, Karen K.
329
2006
32
African swine fever
Dixon, L. K.
Sun, H.
Roberts, H.
324
2019
33
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009)
de Bethune, Marie-Pierre
323
2010
34
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Broder, Samuel
320
2010
35
Herpes simplex encephalitis: Adolescents and adults
Whitley, Richard J.
319
2006
36
The SARS coronavirus nucleocapsid protein - Forms and functions
Chang, Chung-ke
Hou, Ming-Hon
Chang, Chi-Fon
Hsiao, Chwan-Deng
Huang, Tai-huang
318
2014
37
Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro
Wang, Gui-Feng
Shi, Li-Ping
Ren, Yu-Dan
Liu, Qun-Fang
Liu, Hou-Fu
Zhang, Ru-Jun
Li, Zhuang
Zhu, Feng-Hua
He, Pei-Lan
Tang, Wei
Tao, Pei-Zhen
Li, Chuan
Zhao, Wei-Min
Zuo, Jian-Ping
315
2009
38
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo
Ives, JAL
Carr, JA
Mendel, DB
Tai, CY
Lambkin, R
Kelly, L
Oxford, JS
Hayden, FG
Roberts, NA
302
2002
39
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
Vangeel, Laura
Chiu, Winston
De Jonghe, Steven
Maes, Piet
Slechten, Bram
Raymenants, Joren
Andre, Emmanuel
Leyssen, Pieter
Neyts, Johan
Jochmans, Dirk
299
2022
40
INHIBITION OF THE INFECTIVITY OF INFLUENZA-VIRUS BY TEA POLYPHENOLS
NAKAYAMA, M
SUZUKI, K
TODA, M
OKUBO, S
HARA, Y
SHIMAMURA, T
299
1993
41
Accessory proteins of SARS-CoV and other coronaviruses
Liu, Ding Xiang
Fung, To Sing
Chong, Kelvin Kian-Long
Shukla, Aditi
Hilgenfeld, Rolf
295
2014
42
Resistance of influenza viruses to neuraminidase inhibitors - a review
McKimm-Breschkin, JL
292
2000
43
Zika virus: History, emergence, biology, and prospects for control
Weaver, Scott C.
Costa, Federico
Garcia-Blanco, Mariano A.
Ko, Albert I.
Ribeiro, Guilherme S.
Saade, George
Shi, Pei-Yong
Vasilakis, Nikos
286
2016
44
Influenza virus resistance to neuraminidase inhibitors
Samson, Melanie
Pizzorno, Andres
Abed, Yacine
Boivin, Guy
286
2013
45
Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research
Simmons, Graham
Zmora, Pawel
Gierer, Stefanie
Heurich, Adeline
Poehlmann, Stefan
282
2013
46
Ten years of dengue drug discovery: Progress and prospects
Lim, Siew Pheng
Wang, Qing-Yin
Noble, Christian G.
Chen, Yen-Liang
Dong, Hongping
Zou, Bin
Yokokawa, Fumiaki
Nilar, Shahul
Smith, Paul
Beer, David
Lescar, Julien
Shi, Pei-Yong
279
2013
47
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
Ray, Adrian S.
Fordyce, Marshall W.
Hitchcock, Michael J. M.
278
2016
48
Antiviral activities of type I interferons to SARS-CoV-2 infection
Mantlo, Emily
Bukreyeva, Natalya
Maruyama, Junki
Paessler, Slobodan
Huang, Cheng
270
2020
49
Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS
Drexler, Jan Felix
Corman, Victor Max
Drosten, Christian
263
2014
50
Antiviral activity of Plantago major extracts and related compounds in vitro
Chiang, LC
Chiang, W
Chang, MY
Ng, LT
Lin, CC
261
2002
51
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Cihlar, Tomas
Ray, Adrian S.
260
2010
52
Chikungunya: Evolutionary history and recent epidemic spread
Weaver, Scott C.
Forrester, Naomi L.
254
2015
53
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
Wensing, Annemarie M. J.
van Maarseveen, Noortje M.
Nijhuis, Monique
247
2010
54
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
Liu, William J.
Zhao, Min
Liu, Kefang
Xu, Kun
Wong, Gary
Tan, Wenjie
Gao, George F.
244
2017
55
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, Leen
Abdelnabi, Rana
Neyts, Johan
241
2018
56
Extracts and molecules from medicinal plants against herpes simplex viruses
Khan, MTH
Ather, A
Thompson, KD
Gambari, R
239
2005
57
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit
Noshi, Takeshi
Kitano, Mitsutaka
Taniguchi, Keiichi
Yamamoto, Atsuko
Omoto, Shinya
Baba, Keiko
Hashimoto, Takashi
Ishida, Kayo
Kushima, Yukihiro
Hattori, Kazunari
Kawai, Makoto
Yoshida, Ryu
Kobayashi, Masanori
Yoshinaga, Tomokazu
Sato, Akihiko
Okamatsu, Masatoshi
Sakoda, Yoshihiro
Kida, Hiroshi
Shishido, Takao
Naito, Akira
238
2018
58
Structure and functionality in flavivirus NS-proteins: Perspectives for drug design
Bollati, Michela
Alvarez, Karin
Assenberg, Rene
Baronti, Cecile
Canard, Bruno
Cook, Shelley
Coutard, Bruno
Decroly, Etienne
de Lamballerie, Xavier
Gould, Ernest A.
Grard, Gilda
Grimes, Jonathan M.
Hilgenfeld, Rolf
Jansson, Anna M.
Malet, Helene
Mancini, Erika J.
Mastrangelo, Eloise
Mattevi, Andrea
Milani, Mario
Moureau, Gregory
Neyts, Johan
Owens, Raymond J.
Ren, Jingshan
Selisko, Barbara
Speroni, Silvia
Steuber, Holger
Stuart, David I.
Unge, Torsten
Bolognesi, Martino
236
2010
59
From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses
Hilgenfeld, Rolf
Peiris, Malik
234
2013
60
The ecology of ticks and epidemiology of tick-borne viral diseases
Estrada-Pena, Agustin
de la Fuente, Jose
232
2014
61
Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210
Zhang, Guang-ling
Li, Yi-xuan
Zheng, Shu-qi
Liu, Min
Li, Xin
Tang, Hua
232
2010
62
A potential role for integrins in host cell entry by SARS-CoV-2
Sigrist, Christian J. A.
Bridge, Alan
Le Mercier, Philippe
232
2020
63
Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding
Mounce, Bryan C.
Cesaro, Teresa
Carrau, Lucia
Vallet, Thomas
Vignuzzi, Marco
231
2017
64
Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses
Crance, JM
Scaramozzino, N
Jouan, A
Garin, D
229
2003
65
Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines
Ruzek, Daniel
Zupanc, Tatjana Avsic
Borde, Johannes
Chrdle, Ales
Eyer, Ludek
Karganova, Galina
Kholodilov, Ivan
Knap, Natasa
Kozlovskaya, Liubov
Matveev, Andrey
Miller, Andrew D.
Osolodkin, Dmitry I.
Overby, Anna K.
Tikunova, Nina
Tkachev, Sergey
Zajkowska, Joanna
228
2019
66
The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts
Mehand, Massinissa Si
Al-Shorbaji, Farah
Millett, Piers
Murgue, Bernadette
227
2018
67
Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
Shannon, Ashleigh
Nhung Thi-Tuyet Le
Selisko, Barbara
Eydoux, Cecilia
Alvarez, Karine
Guillemot, Jean-Claude
Decroly, Etienne
Peersen, Olve
Ferron, Francois
Canard, Bruno
223
2020
68
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa
Hurt, Aeron C.
Ernest, Joanne
Deng, Yi-Mo
Iannello, Pina
Besselaar, Terry G.
Birch, Chris
Buchy, Philippe
Chittaganpitch, Malinee
Chiu, Shu-Chun
Dwyer, Dominic
Guigon, Aurelie
Harrower, Bruce
Kei, Ip Peng
Kok, Tuckweng
Lin, Cui
McPhie, Ken
Mohd, Apandi
Olveda, Remigio
Panayotou, Tony
Rawlinson, William
Scott, Lesley
Smith, David
D'Souza, Holly
Komadina, Naomi
Shaw, Robert
Kelso, Anne
Barr, Ian G.
222
2009
69
Strategies for development of dengue virus inhibitors
Noble, Christian G.
Chen, Yen-Liang
Dong, Hongping
Gu, Feng
Lim, Siew Pheng
Schul, Wouter
Wang, Qing-Yin
Shi, Pei-Yong
218
2010
70
Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions
Kim, So Young
Jin, Weihua
Sood, Amika
Montgomery, David W.
Grant, Oliver C.
Fuster, Mark M.
Fu, Li
Dordick, Jonathan S.
Woods, Robert J.
Zhang, Fuming
Linhardt, Robert J.
216
2020
71
Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle
Keyaerts, Els
Vijgen, Leen
Pannecouque, Christophe
Van Damme, Els
Peumans, Willy
Egberink, Herman
Balzarini, Jan
Van Ranst, Marc
212
2007
72
Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin
Tay, M. Y. F.
Fraser, J. E.
Chan, W. K. K.
Moreland, N. J.
Rathore, A. P.
Wang, C.
Vasudevan, S. G.
Jans, D. A.
212
2013
73
Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol
Leneva, Irina A.
Russell, Rupert J.
Boriskin, Yury S.
Hay, Alan J.
211
2009
74
THE MANNOSE-SPECIFIC PLANT-LECTINS FROM CYMBIDIUM HYBRID AND EPIPACTIS-HELLEBORINE AND THE (N-ACETYLGLUCOSAMINE)N-SPECIFIC PLANT LECTIN FROM URTICA-DIOICA ARE POTENT AND SELECTIVE INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS AND CYTOMEGALOVIRUS REPLICATION INVITRO
BALZARINI, J
NEYTS, J
SCHOLS, D
HOSOYA, M
VANDAMME, E
PEUMANS, W
DECLERCQ, E
210
1992
75
The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer
Yang, Sundy N. Y.
Atkinson, Sarah C.
Wang, Chunxiao
Lee, Alexander
Bogoyevitch, Marie A.
Borg, Natalie A.
Jans, David A.
210
2020
76
INHIBITORY EFFECT OF GLYCYRRHIZIN ON THE INVITRO INFECTIVITY AND CYTOPATHIC ACTIVITY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS [HIV(HTLV-III/LAV)]
ITO, M
NAKASHIMA, H
BABA, M
PAUWELS, R
DECLERCQ, E
SHIGETA, S
YAMAMOTO, N
205
1987
77
The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development
Luo, Dahai
Vasudevan, Subhash G.
Lescar, Julien
204
2015
78
The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell
Talarico, LB
Pujol, CA
Zibetti, RGM
Faría, PCS
Noseda, MD
Duarte, MER
Damonte, EB
204
2005
79
Current status and challenges of antiretroviral research and therapy
Este, Jose A.
Cihlar, Tomas
202
2010
80
Core protein: A pleiotropic keystone in the HBV lifecycle
Zlotnick, Adam
Venkatakrishnan, Balasubramanian
Tan, Zhenning
Lewellyn, Eric
Turner, William
Francis, Samson
199
2015
81
Current and future antiviral therapy of severe seasonal and avian influenza
Beigel, John
Bray, Mike
199
2008
82
Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system
Romero, MR
Efferth, T
Serrano, MA
Castaño, B
Macias, RIR
Briz, O
Marin, JJG
198
2005
83
PENTOSAN POLYSULFATE, A SULFATED OLIGOSACCHARIDE, IS A POTENT AND SELECTIVE ANTI-HIV AGENT INVITRO
BABA, M
NAKAJIMA, M
SCHOLS, D
PAUWELS, R
BALZARINI, J
DECLERCQ, E
197
1988
84
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)
DeVincenzo, John
Cehelsky, Jeffrey E.
Alvarez, Rene
Elbashir, Ayda
Elbashir, Sayda
Harborth, Jens
Toudjarska, Iva
Nechev, Lubornir
Murugaiah, Veeravagu
Van Vliet, Andre
Vaishnaw, Akshay K.
Meyers, Rachel
196
2008
85
Treatment of Argentine hemorrhagic fever
Enria, Delia A.
Briggiler, Ana M.
Sanchez, Zaida
195
2008
86
Anti-hepatitis B virus activity of wogonin in vitro and in vivo
Guo, Qinglong
Zhao, Li
You, Qidong
Yang, Yong
Gu, Hongyan
Song, Guoliang
Lu, Na
Xin, Jian
193
2007
87
Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections
Baker, R
Bray, M
Huggins, JW
192
2003
88
Receptor recognition and cross-species infections of SARS coronavirus
Li, Fang
192
2013
89
Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents
Hwu, Jih Ru
Singha, Raghunath
Hong, Shih Ching
Chang, Yung Hsiung
Das, Asish R.
Vliegen, Inge
De Clercq, Erik
Neyts, Johan
192
2008
90
Molecular targets for flavivirus drug discovery
Sampath, Aruna
Padmanabhan, R.
192
2009
91
Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities
Gish, Robert G.
Given, Bruce D.
Lai, Ching-Lung
Locarnini, Stephen A.
Lau, Johnson Y. N.
Lewis, David L.
Schluep, Thomas
191
2015
92
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
Tong, Xiao
Chase, Robert
Skelton, Angela
Chen, Tong
Wright-Minogue, Jackie
Malcolm, Bruce A.
191
2006
93
Vaccinia virus vaccines: Past, present and future
Jacobs, Bertram L.
Langland, Jeffrey O.
Kibler, Karen V.
Denzier, Karen L.
White, Stacy D.
Holechek, Susan A.
Wong, Shukmei
Huynh, Trung
Baskin, Carole R.
188
2009
94
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication
Dong, Chunsheng
Qu, Liang
Wang, Haoyi
Wei, Lin
Dong, Yuansu
Xiong, Sidong
186
2015
95
L-Nucleoside enantiomers as antivirals drugs:: A mini-review
Mathe, Christophe
Gosselin, Gilles
186
2006
96
Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
Lin, Min-Han
Moses, David C.
Hsieh, Chih-Hua
Cheng, Shu-Chun
Chen, Yau-Hung
Sun, Chiao-Yin
Chou, Chi-Yuan
185
2018
97
Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art
Hostetler, Karl Y.
185
2009
98
Cidofovir in the treatment of poxvirus infections
De Clercq, E
184
2002
99
The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold
Yates, Mary K.
Seley-Radtke, Katherine L.
183
2019
100
The olive leaf extract exhibits antiviral activity against viral ha emorrhagic septicaemia rhabdovirus (VHSV)
Micol, V
Caturla, N
Pérez-Fons, L
Más, V
Pérez, L
Estepa, A
182
2005